Keros Therapeutics, Inc.
KROS
$10.93
-$0.42-3.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 146.44% | 135.50% | 111.17% | 102.63% | -22.46% |
| Total Depreciation and Amortization | 22.78% | 25.96% | 30.77% | 40.11% | 50.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.26% | -4.75% | 10.13% | 16.04% | 21.02% |
| Change in Net Operating Assets | -5.89% | -281.62% | 74.50% | 120.37% | -331.58% |
| Cash from Operations | 166.83% | 163.28% | 138.27% | 133.27% | -29.20% |
| Capital Expenditure | 19.68% | 21.85% | 16.49% | 33.99% | 21.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 19.68% | 21.85% | 16.49% | 33.99% | 21.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.93% | -80.39% | 0.59% | 2.97% | 119.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 130.62% | 100.00% | 68.90% | 44.76% | -382.98% |
| Cash from Financing | -196.59% | -80.36% | 0.71% | 3.04% | 118.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -218.99% | -33.02% | 239.92% | 206.20% | 340.56% |